Overview

Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

Status:
Terminated
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
Participants responding well in Study FE200486 CS06 (NCT00117949) were given the opportunity to continue treatment with degarelix under a clinical study until FE200486 was available on the market or until the study was discontinued. Study FE200486 CS06A was to provide knowledge of the long-term safety and tolerability of FE200486.
Phase:
Phase 2
Details
Lead Sponsor:
Ferring Pharmaceuticals